SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $12.00.

A number of equities research analysts recently weighed in on the company. Citigroup assumed coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $11.00 price target on the stock. Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 10th. Chardan Capital raised their price target on SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Finally, Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th.

Hedge Funds Weigh In On SAB Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. acquired a new position in SAB Biotherapeutics during the first quarter worth about $29,000. ADAR1 Capital Management LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $32,000. State of Wyoming purchased a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $34,000. Finally, Virtu Financial LLC purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $40,000. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $3.77 on Tuesday. The company has a market cap of $343.03 million, a P/E ratio of -2.90 and a beta of 0.53. SAB Biotherapeutics has a one year low of $1.85 and a one year high of $5.15. The business has a fifty day moving average of $3.72 and a two-hundred day moving average of $3.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). As a group, analysts predict that SAB Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.